Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. VYNE Therapeutics Inc.
  6. News
  7. Summary
    VYNE   US92941V2097

VYNE THERAPEUTICS INC.

(VYNE)
  Report
Delayed Nasdaq  -  04:00 2022-07-01 pm EDT
0.4370 USD   +12.37%
06/17VYNE Therapeutics Completes Enrollment in Trial of Atopic Dermatitis Treatment
MT
06/17VYNE THERAPEUTICS : Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis - Form 8-K
PU
06/17VYNE THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Transcript : VYNE Therapeutics Inc. - Special Call

05/17/2022 | 10:00am EDT
share with twitter
share with LinkedIn
share with facebook
Good morning, and welcome to the VYNE Therapeutics KOL event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the VYNE website following...


© S&P Capital IQ 2022
All news about VYNE THERAPEUTICS INC.
06/17VYNE Therapeutics Completes Enrollment in Trial of Atopic Dermatitis Treatment
MT
06/17VYNE THERAPEUTICS : Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of ..
PU
06/17VYNE THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Other Events, Financi..
AQ
06/17VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of..
AQ
06/17VYNE Therapeutics Inc. Completes Enrollment in Phase 2A Trial of FMX 114 for the Treatm..
CI
05/18VYNE Therapeutics to Present at HC Wainwright & Co. Global Investment Conference
AQ
05/17VYNE THERAPEUTICS INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form..
AQ
05/17TRANSCRIPT : VYNE Therapeutics Inc. - Special Call
CI
05/12VYNE THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and..
AQ
05/12Earnings Flash (VYNE) VYNE THERAPEUTICS Reports Q1 Loss $-0.14
MT
More news
Analyst Recommendations on VYNE THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2022 0,43 M - -
Net income 2022 -37,4 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,75x
Yield 2022 -
Capitalization 25,3 M 25,3 M -
Capi. / Sales 2022 58,5x
Capi. / Sales 2023 101x
Nbr of Employees 28
Free-Float 98,5%
Chart VYNE THERAPEUTICS INC.
Duration : Period :
VYNE Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VYNE THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 0,44 $
Average target price 6,00 $
Spread / Average Target 1 273%
EPS Revisions
Managers and Directors
David Domzalski President, Chief Executive Officer & Director
Tyler Zeronda Chief Financial Officer & Treasurer
Iain A. Stuart Chief Scientific Officer
Sharon Barbari Independent Director
Steven L. Basta Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VYNE THERAPEUTICS INC.-57.16%25
JOHNSON & JOHNSON4.94%472 389
PFIZER, INC.-11.41%293 506
ELI LILLY AND COMPANY17.55%292 291
ROCHE HOLDING AG-14.90%274 360
ABBVIE INC.13.59%271 782